X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DIVIS LABORATORIES - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DIVIS LABORATORIES ORCHID PHARMA LTD/
DIVIS LABORATORIES
 
P/E (TTM) x -0.8 18.5 - View Chart
P/BV x 0.6 4.0 14.1% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ORCHID PHARMA LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES
Mar-16
ORCHID PHARMA LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1942,484 7.8%   
Low Rs35918 3.8%   
Sales per share (Unadj.) Rs276.5142.3 194.3%  
Earnings per share (Unadj.) Rs-79.241.9 -189.1%  
Cash flow per share (Unadj.) Rs-43.546.3 -93.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs53.9161.5 33.4%  
Shares outstanding (eoy) m70.45265.47 26.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.412.0 3.5%   
Avg P/E ratio x-1.440.6 -3.6%  
P/CF ratio (eoy) x-2.636.7 -7.2%  
Price / Book Value ratio x2.110.5 20.2%  
Dividend payout %023.9 0.0%   
Avg Mkt Cap Rs m8,067451,525 1.8%   
No. of employees `0002.83.7 75.5%   
Total wages/salary Rs m2,5273,649 69.2%   
Avg. sales/employee Rs Th6,956.110,184.4 68.3%   
Avg. wages/employee Rs Th902.5984.1 91.7%   
Avg. net profit/employee Rs Th-1,993.02,998.5 -66.5%   
INCOME DATA
Net Sales Rs m19,47737,764 51.6%  
Other income Rs m407848 48.0%   
Total revenues Rs m19,88438,612 51.5%   
Gross profit Rs m1,10314,138 7.8%  
Depreciation Rs m2,5191,182 213.2%   
Interest Rs m5,22723 22,529.3%   
Profit before tax Rs m-6,23613,781 -45.3%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,662 -4.7%   
Profit after tax Rs m-5,58011,119 -50.2%  
Gross profit margin %5.737.4 15.1%  
Effective tax rate %2.019.3 10.4%   
Net profit margin %-28.729.4 -97.3%  
BALANCE SHEET DATA
Current assets Rs m11,01430,947 35.6%   
Current liabilities Rs m32,0605,195 617.1%   
Net working cap to sales %-108.168.2 -158.5%  
Current ratio x0.36.0 5.8%  
Inventory Days Days95117 81.3%  
Debtors Days Days3485 39.4%  
Net fixed assets Rs m29,44017,027 172.9%   
Share capital Rs m705531 132.7%   
"Free" reserves Rs m2,04342,341 4.8%   
Net worth Rs m3,80042,877 8.9%   
Long term debt Rs m9,0185 191,870.2%   
Total assets Rs m46,51049,684 93.6%  
Interest coverage x-0.2595.0 -0.0%   
Debt to equity ratio x2.40 2,165,009.4%  
Sales to assets ratio x0.40.8 55.1%   
Return on assets %-0.822.4 -3.4%  
Return on equity %-146.925.9 -566.3%  
Return on capital %-3.732.2 -11.6%  
Exports to sales %37.985.3 44.4%   
Imports to sales %22.622.9 98.7%   
Exports (fob) Rs m7,37832,198 22.9%   
Imports (cif) Rs m4,4068,654 50.9%   
Fx inflow Rs m7,51332,270 23.3%   
Fx outflow Rs m5,6498,775 64.4%   
Net fx Rs m1,86523,496 7.9%   
CASH FLOW
From Operations Rs m1,68210,379 16.2%  
From Investments Rs m-9,860-4,135 238.5%  
From Financial Activity Rs m6,644-6,241 -106.4%  
Net Cashflow Rs m-1,5353 -46,515.2%  

Share Holding

Indian Promoters % 32.3 52.0 62.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.8 39.0%  
FIIs % 3.3 19.0 17.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.2 321.5%  
Shareholders   84,811 31,796 266.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   PLETHICO PHARMA  BIOCON LTD  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 17, 2017 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS